115 related articles for article (PubMed ID: 35822241)
1. Increased
Park SJ; Frake RA; Rubinsztein DC
Autophagy; 2023 Mar; 19(3):943-944. PubMed ID: 35822241
[TBL] [Abstract][Full Text] [Related]
2. Vinexin contributes to autophagic decline in brain ageing across species.
Park SJ; Frake RA; Karabiyik C; Son SM; Siddiqi FH; Bento CF; Sterk P; Vicinanza M; Pavel M; Rubinsztein DC
Cell Death Differ; 2022 May; 29(5):1055-1070. PubMed ID: 34848853
[TBL] [Abstract][Full Text] [Related]
3. Cell type-specific YAP1-WWTR1/TAZ transcriptional responses after autophagy perturbations are determined by levels of α-catenins (CTNNA1 and CTNNA3).
Pavel M; Park SJ; Tanasa R; Rubinsztein DC
Autophagy; 2021 Jul; 17(7):1788-1790. PubMed ID: 34036899
[TBL] [Abstract][Full Text] [Related]
4. An amphipathic helix of vinexin α is necessary for a substrate stiffness-dependent conformational change in vinculin.
Hino N; Ichikawa T; Kimura Y; Matsuda M; Ueda K; Kioka N
J Cell Sci; 2019 Jan; 132(2):. PubMed ID: 30578314
[TBL] [Abstract][Full Text] [Related]
5. Loss of
Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A
Development; 2018 Mar; 145(6):. PubMed ID: 29511023
[TBL] [Abstract][Full Text] [Related]
6. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
[TBL] [Abstract][Full Text] [Related]
7. Zebrafish mutants and TEAD reporters reveal essential functions for Yap and Taz in posterior cardinal vein development.
Astone M; Lai JKH; Dupont S; Stainier DYR; Argenton F; Vettori A
Sci Rep; 2018 Jul; 8(1):10189. PubMed ID: 29976931
[TBL] [Abstract][Full Text] [Related]
8. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
9. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
10. Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases.
Li R; Huang W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675179
[TBL] [Abstract][Full Text] [Related]
11. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
12. An optogenetic method for interrogating YAP1 and TAZ nuclear-cytoplasmic shuttling.
Dowbaj AM; Jenkins RP; Williamson D; Heddleston JM; Ciccarelli A; Fallesen T; Hahn KM; O'Dea RD; King JR; Montagner M; Sahai E
J Cell Sci; 2021 Jul; 134(13):. PubMed ID: 34060624
[TBL] [Abstract][Full Text] [Related]
13. Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix.
Kim SH; Basili T; Dopeso H; Da Cruz Paula A; Bi R; Issa Bhaloo S; Pareja F; Li Q; da Silva EM; Zhu Y; Hoang T; Selenica P; Murali R; Chan E; Wu M; Derakhshan F; Maroldi A; Hanlon E; Ferreira CG; Lapa E Silva JR; Abu-Rustum NR; Zamarin D; Chandarlapaty S; Matrai C; Yoon JY; Reis-Filho JS; Park KJ; Weigelt B
J Pathol; 2022 Aug; 257(5):635-649. PubMed ID: 35411948
[TBL] [Abstract][Full Text] [Related]
14. Role of smooth muscle YAP and TAZ in protection against phenotypic modulation, inflammation, and aneurysm development.
Daoud F; Arévalo Martínez M; Holst J; Holmberg J; Albinsson S; Swärd K
Biochem Pharmacol; 2022 Dec; 206():115307. PubMed ID: 36270325
[TBL] [Abstract][Full Text] [Related]
15. Wnt16 Promotes Vascular Smooth Muscle Contractile Phenotype and Function via Taz (Wwtr1) Activation in Male LDLR-/- Mice.
Behrmann A; Zhong D; Li L; Xie S; Mead M; Sabaeifard P; Goodarzi M; Lemoff A; Kozlitina J; Towler DA
Endocrinology; 2023 Dec; 165(2):. PubMed ID: 38123514
[TBL] [Abstract][Full Text] [Related]
16. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of YAP1 and TAZ in esophageal squamous cell carcinoma.
Liu L; Lu Z; Hu X; Su T; Su L; Pu H
Medicine (Baltimore); 2021 Jul; 100(28):e26597. PubMed ID: 34260541
[TBL] [Abstract][Full Text] [Related]
18. Vinculin promotes nuclear localization of TAZ to inhibit ECM stiffness-dependent differentiation into adipocytes.
Kuroda M; Wada H; Kimura Y; Ueda K; Kioka N
J Cell Sci; 2017 Mar; 130(5):989-1002. PubMed ID: 28115535
[TBL] [Abstract][Full Text] [Related]
19. eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Strnadel J; Choi S; Fujimura K; Wang H; Zhang W; Wyse M; Wright T; Gross E; Peinado C; Park HW; Bui J; Kelber J; Bouvet M; Guan KL; Klemke RL
Cancer Res; 2017 Apr; 77(8):1997-2007. PubMed ID: 28381547
[TBL] [Abstract][Full Text] [Related]
20. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
